Compare
Tenon Medical, Inc. vs Intelligent Bio Solutions Inc. vs Nuo Therapeutics, Inc. vs Lucid Diagnostics Inc.
| Latest fiscal year | Tenon Medical, Inc. TNON | Intelligent Bio Solutions Inc. INBS | Nuo Therapeutics, Inc. AURX | Lucid Diagnostics Inc. LUCD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.94M | $4.22M | $3.31M | $4.71M |
| Revenue growth (YoY) | +20.4% | +38.1% | +142.7% | +8.3% |
| Gross margin | 59.8% | 48.6% | 66.9% | -41.7% (computed) |
| Operating margin | -324.3% | -299.1% | -76.0% | n/m |
| Net margin | -318.4% | -294.9% | -75.8% | n/m |
| Net income | -$12.56M | -$12.43M | -$2.51M | -$58.01M |
| EPS (Diluted) | -$1.70 | -$8.44 | n/a | n/a |
| Operating cash flow | -$10.74M | -$11.93M | -$865.0K | -$46.48M |
| Free cash flow | -$11.02M | -$12.05M | -$1.14M | -$46.68M |
| Cash & equivalents | $3.76M | $3.99M | $548.9K | n/a |
| Total assets | $10.76M | $11.94M | $1.85M | $40.45M |
| Total liabilities | $5.72M | $6.65M | $2.80M | $29.51M |
| Shareholders' equity | $5.04M | $5.51M | -$956.6K | $10.94M |
| Return on year-end equity | -249.1% | -225.6% | n/a | -530.4% |
| Shares outstanding | 10.85M | 2.91M | 48.18M | 131.10M |
Revenue, most recent five fiscal years
| Fiscal year | Tenon Medical, Inc. | Intelligent Bio Solutions Inc. | Nuo Therapeutics, Inc. | Lucid Diagnostics Inc. |
|---|---|---|---|---|
| Latest | $3.94M Ended 2025-12-31 | $4.22M Ended 2026-06-30 | $3.31M Ended 2025-12-31 | $4.71M Ended 2025-12-31 |
| 1 year earlier | $3.28M Ended 2024-12-31 | $3.05M Ended 2025-06-30 | $1.37M Ended 2024-12-31 | $4.35M Ended 2024-12-31 |
| 2 years earlier | $2.93M Ended 2023-12-31 | $3.11M Ended 2024-06-30 | $608.5K Ended 2023-12-31 | $2.43M Ended 2023-12-31 |
| 3 years earlier | $691.0K Ended 2022-12-31 | $1.26M Ended 2023-06-30 | $112.2K Ended 2022-12-31 | $377.0K Ended 2022-12-31 |
| 4 years earlier | $160.0K Ended 2021-12-31 | $437.1K Ended 2022-06-30 | $0 Ended 2021-12-31 | $500.0K Ended 2021-12-31 |